A Phase I, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 anti-LAG-3 mAb Administered Alone or in Combination with REGN2810 anti-PD-1 mAb in Patients with Advanced Malignancies
A Study of the Safety and Effectiveness of the Mentor� Smooth and Textured Larger Size MemoryGel� Ultra High Profile UHP-L Breast Implants in Subjects who are undergoing
Primary Breast Reconstruction or Revision Reconstruction ?Athena Study?
Elacestrant Monotherapy for the Treatment of Postmenopausal Women with ER+/HER2- Advanced Breast Cancer Following Cdk4/6 Inhibitor Therapy: A Phase III Randomized, Open-Label, Multicenter Trial EMERALD
The GLORIA Study: A Phase III, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin OBI-822/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
Randomized Open-Label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic GI Cancers